These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 34349756)

  • 1. Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level.
    Copley HC; Gragert L; Leach AR; Kosmoliaptsis V
    Front Immunol; 2021; 12():669357. PubMed ID: 34349756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics.
    Nagler A; Kalaora S; Barbolin C; Gangaev A; Ketelaars SLC; Alon M; Pai J; Benedek G; Yahalom-Ronen Y; Erez N; Greenberg P; Yagel G; Peri A; Levin Y; Satpathy AT; Bar-Haim E; Paran N; Kvistborg P; Samuels Y
    Cell Rep; 2021 Jun; 35(13):109305. PubMed ID: 34166618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes.
    Braun A; Rowntree LC; Huang Z; Pandey K; Thuesen N; Li C; Petersen J; Littler DR; Raji S; Nguyen THO; Jappe Lange E; Persson G; Schantz Klausen M; Kringelum J; Chung S; Croft NP; Faridi P; Ayala R; Rossjohn J; Illing PT; Scull KE; Ramarathinam S; Mifsud NA; Kedzierska K; Sørensen AB; Purcell AW
    Nat Commun; 2024 Aug; 15(1):7547. PubMed ID: 39214998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage.
    Karami Fath M; Jahangiri A; Ganji M; Sefid F; Payandeh Z; Hashemi ZS; Pourzardosht N; Hessami A; Mard-Soltani M; Zakeri A; Rahbar MR; Khalili S
    Front Immunol; 2021; 12():705772. PubMed ID: 34447375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicted HLA Class I and Class II Epitopes From Licensed Vaccines Are Largely Conserved in New SARS-CoV-2 Omicron Variant of Concern.
    López D
    Front Immunol; 2022; 13():832889. PubMed ID: 35154154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells.
    Parker R; Partridge T; Wormald C; Kawahara R; Stalls V; Aggelakopoulou M; Parker J; Powell Doherty R; Ariosa Morejon Y; Lee E; Saunders K; Haynes BF; Acharya P; Thaysen-Andersen M; Borrow P; Ternette N
    Cell Rep; 2021 May; 35(8):109179. PubMed ID: 34004174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-Predicted MHC Class II Epitope Presentation of SARS-CoV-2 Structural Proteins Correlates to the Case Fatality Rates of COVID-19 in Different Countries.
    Liang C; Bencurova E; Psota E; Neurgaonkar P; Prelog M; Scheller C; Dandekar T
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA Variation and SARS-CoV-2 Specific Antibody Response.
    Wolday D; Fung CYJ; Morgan G; Casalino S; Frangione E; Taher J; Lerner-Ellis JP
    Viruses; 2023 Mar; 15(4):. PubMed ID: 37112884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs.
    Weingarten-Gabbay S; Klaeger S; Sarkizova S; Pearlman LR; Chen DY; Gallagher KME; Bauer MR; Taylor HB; Dunn WA; Tarr C; Sidney J; Rachimi S; Conway HL; Katsis K; Wang Y; Leistritz-Edwards D; Durkin MR; Tomkins-Tinch CH; Finkel Y; Nachshon A; Gentili M; Rivera KD; Carulli IP; Chea VA; Chandrashekar A; Bozkus CC; Carrington M; ; Bhardwaj N; Barouch DH; Sette A; Maus MV; Rice CM; Clauser KR; Keskin DB; Pregibon DC; Hacohen N; Carr SA; Abelin JG; Saeed M; Sabeti PC
    Cell; 2021 Jul; 184(15):3962-3980.e17. PubMed ID: 34171305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-C*04:01 Affects HLA Class I Heterozygosity and Predicted Affinity to SARS-CoV-2 Peptides, and in Combination With Age and Sex of Armenian Patients Contributes to COVID-19 Severity.
    Hovhannisyan A; Madelian V; Avagyan S; Nazaretyan M; Hyussyan A; Sirunyan A; Arakelyan R; Manukyan Z; Yepiskoposyan L; Mayilyan KR; Jordan F
    Front Immunol; 2022; 13():769900. PubMed ID: 35185875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.
    Oyarzun P; Kashyap M; Fica V; Salas-Burgos A; Gonzalez-Galarza FF; McCabe A; Jones AR; Middleton D; Kobe B
    Front Immunol; 2021; 12():598778. PubMed ID: 33717077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.
    Cun Y; Li C; Shi L; Sun M; Dai S; Sun L; Shi L; Yao Y
    Hum Vaccin Immunother; 2021 Apr; 17(4):1097-1108. PubMed ID: 33175614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen presentation in SARS-CoV-2 infection: the role of class I HLA and ERAP polymorphisms.
    Saulle I; Vicentini C; Clerici M; Biasin M
    Hum Immunol; 2021 Aug; 82(8):551-560. PubMed ID: 34116863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PopCover-2.0. Improved Selection of Peptide Sets With Optimal HLA and Pathogen Diversity Coverage.
    Nilsson JB; Grifoni A; Tarke A; Sette A; Nielsen M
    Front Immunol; 2021; 12():728936. PubMed ID: 34484239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Analysis of CD4
    Hyun YS; Lee YH; Jo HA; Baek IC; Kim SM; Sohn HJ; Kim TG
    Front Immunol; 2021; 12():774491. PubMed ID: 35069546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection.
    Augusto DG; Hollenbach JA
    Curr Opin Immunol; 2022 Jun; 76():102178. PubMed ID: 35462277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection.
    Ansari A; Arya R; Sachan S; Jha SN; Kalia A; Lall A; Sette A; Grifoni A; Weiskopf D; Coshic P; Sharma A; Gupta N
    Front Immunol; 2021; 12():636768. PubMed ID: 33777028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-E*01:01 + HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03 + HLA-E*01:03 genotype is associated with more severe disease.
    Hosseini E; Minagar A; Ghasemzadeh M; Arabkhazaeli A; Ghasemzadeh A
    Hum Immunol; 2023 Apr; 84(4):263-271. PubMed ID: 36822912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2.
    Tarabini RF; Rigo MM; Faustino Fonseca A; Rubin F; Bellé R; Kavraki LE; Ferreto TC; Amaral Antunes D; de Souza APD
    Front Immunol; 2021; 12():812176. PubMed ID: 35095907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.
    Lee E; Sandgren K; Duette G; Stylianou VV; Khanna R; Eden JS; Blyth E; Gottlieb D; Cunningham AL; Palmer S
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33443088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.